Pier Capital LLC Has $3.60 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Pier Capital LLC lessened its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 132,604 shares of the company’s stock after selling 1,687 shares during the period. Pier Capital LLC’s holdings in Structure Therapeutics were worth $3,596,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Point72 Asset Management L.P. lifted its position in shares of Structure Therapeutics by 196.5% in the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after buying an additional 820,589 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the last quarter. Vestal Point Capital LP boosted its position in Structure Therapeutics by 105.4% during the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the period. FMR LLC grew its holdings in Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after purchasing an additional 383,635 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Structure Therapeutics by 230.0% in the third quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock valued at $23,936,000 after purchasing an additional 380,115 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GPCR has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. William Blair began coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating for the company. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Up 0.4 %

GPCR stock opened at $21.05 on Tuesday. Structure Therapeutics Inc. has a twelve month low of $19.39 and a twelve month high of $62.74. The company has a market cap of $1.21 billion, a PE ratio of -28.45 and a beta of -2.37. The business’s 50-day simple moving average is $24.71 and its 200 day simple moving average is $31.63.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. On average, equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.